このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Recordati Industria Chimica e Farmaceutica 将来の成長

Future 基準チェック /36

Recordati Industria Chimica e Farmaceutica利益と収益がそれぞれ年間9.2%と5.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に25.8% 9%なると予測されています。

主要情報

9.2%

収益成長率

9.0%

EPS成長率

Pharmaceuticals 収益成長	14.2%
収益成長率	5.5%
将来の株主資本利益率	25.8%
アナリストカバレッジ	Good
最終更新日	17 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

BATS-CHIXE:RECm - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,558	555	611	706	6
12/31/2025	2,442	522	538	661	8
12/31/2024	2,301	474	488	693	9
3/31/2024	2,139	389	154	528	N/A
12/31/2023	2,082	389	102	485	N/A
9/30/2023	2,032	375	134	510	N/A
6/30/2023	2,005	389	438	507	N/A
3/31/2023	1,985	340	360	456	N/A
12/31/2022	1,853	312	367	462	N/A
9/30/2022	1,801	331	391	485	N/A
6/30/2022	1,702	330	422	504	N/A
3/31/2022	1,615	393	445	491	N/A
12/31/2021	1,580	386	404	492	N/A
9/30/2021	1,511	377	373	475	N/A
6/30/2021	1,460	365	303	413	N/A
3/31/2021	1,404	334	259	425	N/A
12/31/2020	1,449	355	272	404	N/A
9/30/2020	1,475	389	-112	362	N/A
6/30/2020	1,499	391	-84	388	N/A
3/31/2020	1,528	388	-101	336	N/A
12/31/2019	1,482	369	-125	319	N/A
9/30/2019	1,439	328	210	318	N/A
6/30/2019	1,399	322	202	301	N/A
3/31/2019	1,369	318	249	346	N/A
12/31/2018	1,352	312	273	358	N/A
9/30/2018	1,338	307	270	362	N/A
6/30/2018	1,333	306	210	307	N/A
3/31/2018	1,313	297	-58	277	N/A
12/31/2017	1,288	289	N/A	273	N/A
9/30/2017	1,255	275	N/A	244	N/A
6/30/2017	1,217	262	N/A	286	N/A
3/31/2017	1,194	250	N/A	273	N/A
12/31/2016	1,154	237	N/A	255	N/A
9/30/2016	1,126	229	N/A	266	N/A
6/30/2016	1,096	218	N/A	261	N/A
3/31/2016	1,074	212	N/A	258	N/A
12/31/2015	1,048	199	N/A	247	N/A
9/30/2015	1,030	190	N/A	231	N/A
6/30/2015	1,019	181	N/A	217	N/A
3/31/2015	1,003	170	N/A	198	N/A
12/31/2014	987	161	N/A	179	N/A
9/30/2014	982	156	N/A	192	N/A
6/30/2014	972	146	N/A	167	N/A
3/31/2014	957	139	N/A	167	N/A
12/31/2013	942	134	N/A	171	N/A
9/30/2013	910	127	N/A	147	N/A
6/30/2013	886	126	N/A	150	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RECmの予測収益成長率 (年間9.2% ) は貯蓄率 ( 1.8% ) を上回っています。

収益対市場: RECmの収益 ( 9.2% ) UK市場 ( 13.1% ) よりも低い成長が予測されています。

高成長収益: RECmの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: RECmの収益 ( 5.5% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: RECmの収益 ( 5.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RECmの自己資本利益率は、3年後には高くなると予測されています ( 25.6 %)

Recordati Industria Chimica e Farmaceutica 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Recent updates

CVC Reportedly Taps Advisors to Study Options for Italy's Recordati

CVC Capital Reportedly Explores Options for its Controlling Stake in Recordati

Recordati Industria Chimica e Farmaceutica S.p.A., Annual General Meeting, Apr 22, 2024

Recordati Industria Chimica e Farmaceutica S.p.A. to Report Fiscal Year 2023 Results on Feb 22, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Full year 2022 earnings released

Recordati Industria Chimica e Farmaceutica S.p.A. to Report First Half, 2023 Results on Jul 28, 2023

Upcoming dividend of €0.55 per share

Second quarter 2022 earnings released: EPS: €0.27 (vs €0.57 in 2Q 2021)

Upcoming dividend of €0.57 per share

First quarter 2022 earnings released: EPS: €0.47 (vs €0.44 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 22% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of €0.53 per share

Third quarter 2021 earnings released: EPS €0.43 (vs €0.38 in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released

Less than half of directors are independent

Upcoming dividend of €0.55 per share

First quarter 2021 earnings released: EPS €0.44 (vs €0.54 in 1Q 2020)

Full year 2020 earnings released: EPS €1.73 (vs €1.80 in FY 2019)

Full year 2020 earnings released

Revenue misses expectations

New 90-day low: €41.91

New 90-day low: €42.01

Recordati Announces the European Medicines Agency Accepts Marketing Authorization Application Submission by ARS Pharmaceuticals for review of ARS-1

ARS Pharmaceuticals, Inc. Announces Licensing Agreement with Recordati for Commercialization of Neffy

ARS Pharmaceuticals, Inc. and Recordati Announce Exclusive License for the Rights in Europe and Additional Countries for Neffy (Ars-1; Epinephrine Nasal Spray)

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘